<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04759092</url>
  </required_header>
  <id_info>
    <org_study_id>TDCS1HB</org_study_id>
    <nct_id>NCT04759092</nct_id>
  </id_info>
  <brief_title>A Four Month Home Based tDCS Study on Patients With Alzheimer's Disease.</brief_title>
  <acronym>tDCS</acronym>
  <official_title>A Four Month Home Based tDCS Study on Patients With Alzheimer's Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Tromso</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital of North Norway</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is an open label study on patients with Alzheimer's dementia using home based&#xD;
      transcranial direct current (tDCS) stimulation. Aims of the study is to investigate&#xD;
      applicability and effect of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Active tDCS of 2mA is applied via surface based electrodes daily for 30 minutes over a 4&#xD;
      month period. Anodal electrode is placed over the left temporal lobe. Participants is&#xD;
      followed up by home visit and phone calls.&#xD;
&#xD;
      Cognitive tests are performed prior to the treatment period, right after finishing 4 months&#xD;
      of treatment and 4 months after treatment is terminated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Actual">May 1, 2021</completion_date>
  <primary_completion_date type="Actual">May 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Treatment study, open label</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate adverse effects of the treatment</measure>
    <time_frame>4 months</time_frame>
    <description>Investigation of tolerability of long term home based tDCS to patients with Alzheimer's by using the Adverse effect questionnaire for tDCS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate effect of the treatment</measure>
    <time_frame>8 months</time_frame>
    <description>Investigate possible change in cognitive tests (Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), Mini Mental Status Examination ( MMSE), Clock drawing test, Trail making test A &amp; B) after 4 months treatment and change 4 months after end of treatment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Treatment with tDCS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Home based treatment with tDCS for four months</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>transcranial direct current stimulation (tDCS)</intervention_name>
    <description>Apply 30min low dose (2mA) transcranial current stimulation on the scalp every day for four months.</description>
    <arm_group_label>Treatment with tDCS</arm_group_label>
    <other_name>tDCS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 60-85.&#xD;
&#xD;
          -  Fulfil diagnostic criteria of probable Alzheimer's dementia.&#xD;
&#xD;
          -  Participants has to live with a caregiver.&#xD;
&#xD;
          -  If medicated with cholinesterase inhibitors or memantine, a stable dose the last three&#xD;
             months before inclusion is required.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Implant in head&#xD;
&#xD;
          -  Seizure history&#xD;
&#xD;
          -  Severe illness,&#xD;
&#xD;
          -  Psychosis or depression measured with a cornell score over 11.&#xD;
&#xD;
          -  Mini mental status (MMSE) score&lt;17.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ole K Grønli Grønli, MD/PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital of North Norway</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of North Norway</name>
      <address>
        <city>Tromsø</city>
        <state>Troms</state>
        <zip>9091</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 28, 2021</study_first_submitted>
  <study_first_submitted_qc>February 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of North Norway</investigator_affiliation>
    <investigator_full_name>Ole Kristian Grønli</investigator_full_name>
    <investigator_title>MD/phd senior consultant</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plan of sharing individual participant data, because its not a part of the approvement of the advisory board.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

